-transparent.png){kind=logo}
Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the clinical and endocrinological responses to treatment in 45 assessable patients. The response rate to Zoladex in this series was 31% and the ER status of the primary tumour was predictive of a response to the luteinising hormone-releasing hormone.
Related Publications
M R Williams, and
K J Walker, and
A Turkes, and
R W Blamey, and
R I Nicholson
March 1986,
Hinyokika kiyo. Acta urologica Japonica,
M R Williams, and
K J Walker, and
A Turkes, and
R W Blamey, and
R I Nicholson
May 1987,
British journal of urology,
M R Williams, and
K J Walker, and
A Turkes, and
R W Blamey, and
R I Nicholson
January 1988,
American journal of clinical oncology,
M R Williams, and
K J Walker, and
A Turkes, and
R W Blamey, and
R I Nicholson
November 1988,
Hinyokika kiyo. Acta urologica Japonica,
M R Williams, and
K J Walker, and
A Turkes, and
R W Blamey, and
R I Nicholson
January 1984,
Journal of steroid biochemistry,
M R Williams, and
K J Walker, and
A Turkes, and
R W Blamey, and
R I Nicholson
February 1988,
Hinyokika kiyo. Acta urologica Japonica,
M R Williams, and
K J Walker, and
A Turkes, and
R W Blamey, and
R I Nicholson
January 1989,
Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
M R Williams, and
K J Walker, and
A Turkes, and
R W Blamey, and
R I Nicholson
January 1987,
Hinyokika kiyo. Acta urologica Japonica,
M R Williams, and
K J Walker, and
A Turkes, and
R W Blamey, and
R I Nicholson
November 1984,
The Journal of endocrinology,
M R Williams, and
K J Walker, and
A Turkes, and
R W Blamey, and
R I Nicholson
April 1989,
European journal of cancer & clinical oncology,
